You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
A new study suggests that Fusobacterium and other microbes may hitch a ride to metastatic sites with primary colorectal cancers, prompting tumor growth.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
The researchers developed a qPCR test that analyzes microRNAs associated with ovarian cancer and plan to run a retrospective trial of the assay on biobanked samples.
The researchers are working to develop portable sequencing solutions for outbreak surveillance and infectious disease diagnostics.
The test is designed to detect and differentiate herpes simplex virus types 1 and 2, Treponema pallidum, and varicella-zoster virus.
Despite the initial high cost, the firm believes the assay's improved accuracy and sensitivity will sway clinical and payor interest.
GenomeDx will have exclusive rights to distribute the molecular tests in most of the US, while Pathnostics continues to perform the assays in-house.
In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.